Ardelyx, INC Form 4 insider transactions

Ardelyx's Chief Business Officer, Mike Kelliher, was granted 103,080 Restricted Stock Units and options to purchase 154,625 shares of common stock.

ARDELYX's Chief Financial Officer, Susan Hohenleitner, acquired 85,670 restricted stock units and 128,505 stock options on January 23, 2026.

Ardelyx's Chief Commercial Officer, Eric Foster, was granted significant equity awards, including restricted stock units and stock options.

Ardelyx, Inc. President and CEO Michael Raab has disclosed future grants of restricted stock units and stock options scheduled for January 23, 2026, under a Rule 10b5-1 plan.

ARDELYX, Inc.'s Chief Human Resources Officer, James Parker Brady, was granted 99,455 restricted stock units and 149,185 stock options.

Laura A. Williams, Chief Patient Officer of Ardelyx, Inc., was granted 82,695 restricted stock units and options to purchase 124,040 shares of common stock.

ARDELYX, Inc. Chief Technical and Quality Officer John Bishop received grants of 124,330 restricted stock units and options to purchase 186,500 shares of common stock.

Ardelyx's Chief Patient Officer, Laura A. Williams, sold 50,000 shares of common stock on January 8, 2026, following the exercise of stock options under a 10b5-1 plan.

ARDELYX Chief Legal and Administrative Officer Elizabeth Grammer sold 5,995 shares of common stock to cover tax withholding upon RSU vesting.

Ardelyx, Inc. President & CEO Michael Raab sold 46,887 shares of common stock to cover tax withholding obligations related to RSU vesting.

ARDELYX, Inc. Chief Business Officer Mike Kelliher sold 5,560 shares of common stock on November 21, 2025, to cover tax obligations from RSU vesting.

ARDELYX Chief Patient Officer Laura A. Williams sold 6,426 shares of common stock to cover tax withholding obligations related to RSU vesting.

Ardelyx's Chief Commercial Officer, Eric Duane Foster, sold 5,814 shares of common stock to cover tax obligations related to RSU vesting.

Ardelyx's Senior VP of Finance, Joseph J. Reilly, sold 11,086 shares of common stock to cover tax obligations related to RSU vesting.

Laura A. Williams, Chief Patient Officer of Ardelyx, Inc., exercised stock options and subsequently sold 80,000 shares of common stock.

Ardelyx Chief Business Officer Mike Kelliher sold 5,417 shares of common stock to cover tax withholding obligations related to RSU vesting.

Ardelyx's Chief Patient Officer, Laura A. Williams, sold 6,261 shares of common stock to cover tax obligations upon the vesting of restricted stock units.

Ardelyx Chief Financial Officer Justin Renz sold 7,037 shares of common stock to cover tax obligations related to RSU vesting.

Ardelyx CEO Michael Raab sold 45,687 shares of common stock on August 21, 2025, to cover tax obligations from vested restricted stock units.

Ardelyx Chief Legal Officer Elizabeth Grammer sold 5,841 shares of common stock to cover tax withholding upon RSU vesting.

Ardelyx's Chief Commercial Officer, Eric Foster, sold 15,308 shares of common stock to cover tax withholding obligations related to RSU vesting.

Ardelyx, Inc. Director Robert B. Bazemore was granted 41,551 restricted stock units and options to purchase 54,059 shares of common stock as part of the company's non-employee director compensation program, effective June 18, 2025.

ARDELYX, Inc. Director Richard J. Rodgers acquired additional common stock, restricted stock units, and stock options as part of the company's Non-Employee Director Compensation Program.

Ardelyx, Inc. Director Merdad Parsey acquired 15,235 shares of common stock as part of the company's non-employee director compensation program, increasing his total beneficial ownership to 57,291 shares.

ARDELYX Director and 10% Owner David M. Mott has increased his beneficial ownership in the company by acquiring common stock, restricted stock units, and stock options as part of the Non-Employee Director Compensation Program.

ARDELYX, Inc. Director Onaiza Cadoret-Manier has reported the acquisition of 41,551 restricted stock units and 54,059 stock options as part of the company's non-employee director compensation program.

ARDELYX, Inc. Director Muna Bhanji was granted 41,551 Restricted Stock Units (RSUs) and options to purchase 54,059 shares of common stock as part of the company's Non-Employee Director Compensation Program.

Ardelyx, Inc. Director William C. Bertrand Jr. acquired additional common stock, restricted stock units, and stock options as part of the company's Non-Employee Director Compensation Program.

ARDELYX Director and 10% Owner David Mott has significantly increased his beneficial ownership in the company by purchasing 200,000 shares of common stock for approximately $725,880.

ARDELYX Director David Mott acquired 200,000 shares of common stock for approximately $737,260, increasing his beneficial ownership to over 2.69 million shares.